Closed Clinical Trials
The table below contains a list of all ECOG-ACRIN clinical trials that have closed to enrollment since January 1, 2021. Hover over any of the column headings and click the up/down arrows to sort. You can also search by keyword. To access more information about a particular trial, click on the trial ID, which will link you to more information.
| Cancer Type | Target Patient Population | Trial ID & Link to info | Study Type | ECOG-ACRIN Oversight Committee(s) | Date Closed |
|---|---|---|---|---|---|
| Various | Metastatic (advanced) solid tumors, lymphomas, or myeloma and also rare cancer types with no standard treatment available | EAY131 / NCI-MATCH | Treatment | Developmental Therapeutics | 12/23/22 |
| Any | Women with a recent cancer diagnosis | E1Q11 / EROS | Reproductive Health Planning | Cancer Control and Survivorship | 03/10/21 |
| Any | Current smokers wanting to stop | EAQ171CD | Observation (Counseling) | Cancer Care Delivery Research | 12/23/22 |
| Any | Cancer patients with pneumonitis (lung inflammation) | EAQ172 | Treatment | Cancer Control and Survivorship | 12/14/23 |
| Anus | Metastatic (advanced) | EA2165 | Treatment | Gastrointestinal | 08/31/21 |
| Bile Duct | Metastatic (advanced) cholangiocarcinoma | EA2187 | Treatment | Gastrointestinal | 03/22/23 |
| Bladder | Has spread to the lymph nodes | EA8185 / INSPIRE | Treatment | Genitourinary | 10/02/23 |
| Blood | Mantle cell lymphoma | EA4181 | Treatment | Lymphoma | 03/31/23 |
| Blood | Acute promyelocytic leukemia (AML) | EA9131 | Treatment | Leukemia; Cancer Control and Survivorship | 06/25/21 |
| Blood | Chronic lymphocytic leukemia (CLL) | EA9161 | Treatment | Leukemia | 04/23/21 |
| Blood | Previously diagnosed with multiple myeloma and on lenalidomide | EAA171 / OPTIMUM | Treatment | Myeloma | 03/03/23 |
| Blood | Acute myeloid leukemia with FLT3 mutation | PrE0905 | Treatment | N/A (PrECOG) | 11/17/22 |
| Brain | Recurrent glioblastoma | EAF151 | Imaging | Brain Cancer Working Group | 08/24/23 |
| Breast | Newly diagnosed, metastatic (advanced) | EAI142 | Imaging | Breast | 07/06/22 |
| Breast | Women who decline the TMIST breast cancer screening trial | EAQ201 | Observation (Patient Reporting)) | Cancer Control and Survivorship | 02/02/23 |
| Breast | Black women with breast cancer | EAZ171 | Treatment | Breast; Prevention | 03/31/22 |
| Breast | Metastatic (advanced) with bone or mostly bone disease | EA1183 / FEATURE | Imaging | Breast | 11/29/23 |
| Breast | Triple negative and basal subtype, including both women and men | EA1131 | Treatment | Breast | 03/30/21 |
| Breast | HER2 positive type | EA1181 / CompassHER2 pCR | Treatment | Breast | 10/12/23 |
| Kidney | Localized (no spread) or limited spread | EA8143 / PROSPER RCC | Treatment | Genitourinary | 06/02/21 |
| Kidney or Thyroid | Blood pressure management | EAQ191 / CARISMA | Treatment | Cancer Control and Survivorship | 12/27/23 |
| Lung | Non-small cell type, metastatic (advanced) | EA5163 / S1709 / INSIGNA | Treatment | Thoracic | 03/01/24 |
| Lung | Non-small cell, non-squamous type | EA5191 | Treatment | Thoracic | 10/13/23 |
| Melanoma (Skin) | Melanoma, metastatic (advanced), and BRAF V600 type | EA6134 / DREAMseq | Treatment | Melanoma | 09/30/21 |
| Melanoma (Skin) | Cutaneous or unknown primary type | EA6183 | Treatment | Melanoma | 09/23/22 |
| Melanoma (Skin) | Advanced, BRAF V600E or BRAF V600K type, and elevated LDH | EA6191 / BAMM2 | Treatment | Melanoma | 03/01/23 |
| Nose and Sinus | Squamous cell type, able to be removed by surgery (operable) | EA3163 | Treatment | Head and Neck | 11/07/23 |
| Pancreas or Gastrointestinal Tract | Locally advanced or metastatic, inoperable | EA2142 | Treatment | Gastrointestinal | 04/01/21 |
| Pancreas | Metastatic (advanced), older (aged 70+) | EA2186 / GIANT | Treatment | Gastrointestinal; Geriatric Oncology Working Group | 10/17/23 |
| Prostate | Metastatic (advanced), hormone sensitive type | EA8153 / CHAARTED2 | Treatment | Genitourinary | 03/26/21 |
| Prostate | Within 6 weeks of surgery (radical prostatectomy) and at highest risk of progression to metastatic (advanced) stage | EA8183 / ERADICATE | Treatment | Genitourinary | 02/09/23 |